Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids

Cancer Letters

Volumn 268, Issue 1, 2008, Pages 166-175

  Liu, Baorui ^a,b   Wang, Tingting ^a   Qian, Xiaoping ^a   Liu, Guangxia ^a   Yu, Lixia ^a   Ding, Yitao ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b Clinical Medical Center for Hepatobiliary Disease in Jiangsu Province   (China)

Author keywords

Ascites; Pleural fluids; Primary cancer cells; Tetrandrine

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; LIPOCORTIN 5; PROTEIN BCL 2; SURVIVIN; TETRANDRINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CELL ISOLATION; CELL STRAIN A549; CELL STRAIN BGC 823; CELL STRAIN LOVO; CELL STRAIN SMMC 7721; CELL VIABILITY; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IC 50; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCITIC FLUID; BENZYLISOQUINOLINES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASM METASTASIS; PLEURAL EFFUSION, MALIGNANT; TIME FACTORS;

EID: 48149086067     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.059     Document Type: Article

References (25)

1. Siyamek N.M. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54 (2006) 1-9
2. Choi H.S., S Kim H., Min K.R., Kim Y., Lim H.K., Chang Y.K., and Chung M.W. Anti-inflammatory effects of fangchinoline and tetrandrine. J. Ethnopharmacol. 69 (2000) 173-179
3. Hui S.C., Chan T.Y., and Chen Y.Y. Tetrandrine inhibits lipid peroxidation but lacks reactivity towards superoxide anion and hydrogen peroxide. Pharmacol. Toxicol. 78 (1996) 200-201
4. Ma J.Y., Barger M.W., Hubbs A.F., Castranova V., Weber S.L., and Ma J.K. Use of tetrandrine to differentiate between mechanisms involved in silica-versus bleomycin-induced fibrosis. J. Toxicol. Environ. Health A 57 (1999) 247-266
5. Chen Y.J. Potential role of tetrandrine in cancer therapy. Acta Pharmacol. Sin. 23 (2002) 1102-1106
6. Dong Y., Yang M.M., and Kwan C.Y. In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci. 60 (1997) 135-140
7. Kuo P.L., and Lin C.C. Tetrandrine-induced cell cycle arrest and apoptosis in Hep G2 cells. Life Sci. 73 (2003) 243-252
8. Liu Z.L., Hirano T., Tanaka S., Onda K., and Oka K. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. J. Pharm. Pharmacol. 55 (2003) 1531-1537
9. Wei J., Liu B.R., Wang L.F., Qian X.P., Ding Y.T., and Yu L.X. Synergistic interaction between tetrandrine and chemotherapeutic agents and influences of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemother. Pharmacol. 60 (2007) 703-711
10. Neale M.H., Lamont A., Hindley A., Kurbacher C.M., and Cree I.A. The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. Anticancer Drugs 11 (2000) 865-871
11. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
12. Richard C., Matthews D., Duivenvoorden W., Yau J., Wright P.S., and Th'ng J.P. Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clin. Cancer Res. 11 (2005) 3523-3529
13. Casale F., D'Angelo V., Addeo R., Caraglia M., Crisci S., Rondelli R., Di Tullio M.T., and Indolfi P. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol. Rep. 12 (2004) 1201-1207
14. Tafuri A., Gregorj C., Petrucci M.T., Ricciardi M.R., Mancini M., Cimino G., Mecucci C., Tedeschi A., Fioritoni G., Ferrara F., Di Raimondo F., and Gallo E. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 100 (2002) 974-981
15. Kwan C.Y., Leung Y.M., Kwan T.K., and Daniel E.E. Tetrandrine inhibits Ca2+ release-activated Ca2+ channels in vascular endothelial cells. Life Sci. 68 (2001) 841-847
16. Ai J., Gao H.H., He S.Z., Wang L., Luo D.L., and Yang B.F. Effects of matrine, artemisinin, tetrandrine on cytosolic [Ca(2+)](i) in guinea pig ventricular myocytes. Acta Pharmacol. Sin. 22 (2001) 512-515
17. Chen L.Y., Chen X., Tian X.L., and Yu X.H. Effects of tetrandrine on calcium transport, protein fluorescences and membrane fluidity of sarcoplasmic reticulum. Br. J. Pharmacol. 131 (2000) 530-536
18. Litman T., Zeuthen T., Skovsgaard T., and Stein W.D. Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1361 (1997) 169-176
19. Cailleau R., Young R., Oilve M., and Reeves W.J. Breast tumor cells lines from pleural effusions. J. Natl. Cancer Inst. 53 (1974) 661-674
20. Flick M.B., O'Malley D., Rutherford T., Rodov S., Kamsteeg M., Hao X.Y., Schwartz P., Kacinski B.M., and Mor G. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J. Soc. Gynecol. Invest. 11 (2004) 252-259
21. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644 (2004) 229-249
22. Manion M.K., and Hockenbery D.M. Targeting bcl-2-related proteins in cancer therapy. Cancer Biol. Ther. 2 (2003) 105-114
23. Suzuki A., Ito T., Hayashida M., Hayasaki Y., Tuutomi Y., Akahane K., Nakano T., Miura M., and Shiraki K. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19 (2000) 1346-1353
24. Haldar S., Jena N., and Croce C.M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA 92 (1995) 4507-4511
25. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22 (2003) 9075-9086